Cargando…

Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study

AIM: To summarize the evidence on clinical effectiveness and safety of wearable cardioverter defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest in patients at risk. METHODS: We performed a systematic literature search in databases including MEDLINE via OVID, Em...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettinger, Sabine, Stanak, Michal, Szymański, Piotr, Wild, Claudia, Tandara Haček, Romana, Erčević, Darija, Grenković, Renata, Huić, Mirjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697444/
https://www.ncbi.nlm.nih.gov/pubmed/29180909
http://dx.doi.org/10.2147/MDER.S144048
_version_ 1783280622773469184
author Ettinger, Sabine
Stanak, Michal
Szymański, Piotr
Wild, Claudia
Tandara Haček, Romana
Erčević, Darija
Grenković, Renata
Huić, Mirjana
author_facet Ettinger, Sabine
Stanak, Michal
Szymański, Piotr
Wild, Claudia
Tandara Haček, Romana
Erčević, Darija
Grenković, Renata
Huić, Mirjana
author_sort Ettinger, Sabine
collection PubMed
description AIM: To summarize the evidence on clinical effectiveness and safety of wearable cardioverter defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest in patients at risk. METHODS: We performed a systematic literature search in databases including MEDLINE via OVID, Embase, the Cochrane Library, and CRD (DARE, NHS-EED, HTA). The evidence obtained was summarized according to GRADE methodology. A health technology assessment (HTA) was conducted using the HTA Core Model(®) for rapid relative effectiveness assessment. Primary outcomes for the clinical effectiveness domain were all-cause and disease-specific mortality. Outcomes for the safety domain were adverse events (AEs) and serious adverse events (SAEs). A focus group with cardiac disease patients was conducted to evaluate ethical, organizational, patient, social, and legal aspects of the WCD use. RESULTS: No randomized- or non-randomized controlled trials were identified. Non-comparative studies (n=5) reported AEs including skin rash/itching (6%), false alarms (14%), and palpitations/light-headedness/fainting (9%) and discontinuation due to comfort/lifestyle issues (16–22%), and SAEs including inappropriate shocks (0–2%), unsuccessful shocks (0–0.7%), and death (0–0.3%). The focus group results reported that experiencing a sense of security is crucial to patients and that the WCD is not considered an option for weeks or even months due to expected restrictions in living a “normal” life. CONCLUSION: The WCD appears to be relatively safe for short-to-medium term, but the quality of existing evidence is very low. AEs and SAEs need to be more appropriately reported in order to further evaluate the safety of the device. High-quality comparative evidence and well-described disease groups are required to assess the effectiveness of the WCD and to determine which patient groups may benefit most from the intervention.
format Online
Article
Text
id pubmed-5697444
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56974442017-11-27 Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study Ettinger, Sabine Stanak, Michal Szymański, Piotr Wild, Claudia Tandara Haček, Romana Erčević, Darija Grenković, Renata Huić, Mirjana Med Devices (Auckl) Original Research AIM: To summarize the evidence on clinical effectiveness and safety of wearable cardioverter defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest in patients at risk. METHODS: We performed a systematic literature search in databases including MEDLINE via OVID, Embase, the Cochrane Library, and CRD (DARE, NHS-EED, HTA). The evidence obtained was summarized according to GRADE methodology. A health technology assessment (HTA) was conducted using the HTA Core Model(®) for rapid relative effectiveness assessment. Primary outcomes for the clinical effectiveness domain were all-cause and disease-specific mortality. Outcomes for the safety domain were adverse events (AEs) and serious adverse events (SAEs). A focus group with cardiac disease patients was conducted to evaluate ethical, organizational, patient, social, and legal aspects of the WCD use. RESULTS: No randomized- or non-randomized controlled trials were identified. Non-comparative studies (n=5) reported AEs including skin rash/itching (6%), false alarms (14%), and palpitations/light-headedness/fainting (9%) and discontinuation due to comfort/lifestyle issues (16–22%), and SAEs including inappropriate shocks (0–2%), unsuccessful shocks (0–0.7%), and death (0–0.3%). The focus group results reported that experiencing a sense of security is crucial to patients and that the WCD is not considered an option for weeks or even months due to expected restrictions in living a “normal” life. CONCLUSION: The WCD appears to be relatively safe for short-to-medium term, but the quality of existing evidence is very low. AEs and SAEs need to be more appropriately reported in order to further evaluate the safety of the device. High-quality comparative evidence and well-described disease groups are required to assess the effectiveness of the WCD and to determine which patient groups may benefit most from the intervention. Dove Medical Press 2017-11-14 /pmc/articles/PMC5697444/ /pubmed/29180909 http://dx.doi.org/10.2147/MDER.S144048 Text en © 2017 Ettinger et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Ettinger, Sabine
Stanak, Michal
Szymański, Piotr
Wild, Claudia
Tandara Haček, Romana
Erčević, Darija
Grenković, Renata
Huić, Mirjana
Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
title Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
title_full Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
title_fullStr Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
title_full_unstemmed Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
title_short Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
title_sort wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697444/
https://www.ncbi.nlm.nih.gov/pubmed/29180909
http://dx.doi.org/10.2147/MDER.S144048
work_keys_str_mv AT ettingersabine wearablecardioverterdefibrillatorsforthepreventionofsuddencardiacarrestahealthtechnologyassessmentandpatientfocusgroupstudy
AT stanakmichal wearablecardioverterdefibrillatorsforthepreventionofsuddencardiacarrestahealthtechnologyassessmentandpatientfocusgroupstudy
AT szymanskipiotr wearablecardioverterdefibrillatorsforthepreventionofsuddencardiacarrestahealthtechnologyassessmentandpatientfocusgroupstudy
AT wildclaudia wearablecardioverterdefibrillatorsforthepreventionofsuddencardiacarrestahealthtechnologyassessmentandpatientfocusgroupstudy
AT tandarahacekromana wearablecardioverterdefibrillatorsforthepreventionofsuddencardiacarrestahealthtechnologyassessmentandpatientfocusgroupstudy
AT ercevicdarija wearablecardioverterdefibrillatorsforthepreventionofsuddencardiacarrestahealthtechnologyassessmentandpatientfocusgroupstudy
AT grenkovicrenata wearablecardioverterdefibrillatorsforthepreventionofsuddencardiacarrestahealthtechnologyassessmentandpatientfocusgroupstudy
AT huicmirjana wearablecardioverterdefibrillatorsforthepreventionofsuddencardiacarrestahealthtechnologyassessmentandpatientfocusgroupstudy